Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
Gangguan fungsi ginjal atau hati dapat terjadi, terutama jika obat digunakan dalam dosis tinggi atau tanpa pengawasan dokter.
doi: 10.1016/j.jaad.2025.06.022
Diabetologia (2011) 54:264959
US$ 29.03
US$ 21.31
US$ 27.32
US$ 23.51
